Quest Diagnostics Inc vs ZIM Integrated Shipping Services Ltd — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while ZIM Integrated Shipping Services Ltd trades at $29.99 (market cap $3.65B). The key difference: Quest Diagnostics Inc is far larger — about 7× ZIM Integrated Shipping Services Ltd's market cap, and ZIM Integrated Shipping Services Ltd pays the higher dividend (20.16%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and ZIM Integrated Shipping Services Ltd for 27 Days on average.
| DGX | ZIM | |
|---|---|---|
Market Cap | $25.48B | $3.65B |
Volume | 941,866 | 1,068,475 |
Sector | Health | Industrials |
52-Week High | $247.45 | $30.51 |
52-Week Low | $173.49 | $12.44 |
Typical Hold Time | 56 Days | 27 Days |
Enterprise Value | $31.23B | $7.32B |
Dividend Yield | 1.49% | 20.16% |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
ZIM Integrated Shipping Services trades at $30.26, up 0.9% today and near its 52-week high of $30.96. The stock shows bullish technical momentum with strong moving average signals, though RSI indicators suggest potential overbought conditions. Fundamentally, Q2 2026 earnings beat expectations with $0.53 EPS versus -$0.02 expected, driven by 9% revenue growth to $1.8 billion. The company faces acquisition uncertainty with Hapag-Lloyd's $35 per share offer pending Israeli government approval.
Investment outlook remains mixed with strong operational performance offset by merger uncertainty. The stock trades at attractive valuations (P/S 0.57, P/B 0.94) but faces headwinds from declining 2026 profit margins (2.15% vs 6.94% in 2025). Analyst consensus leans cautious with 67% hold ratings, while technical indicators suggest near-term resistance at current levels. Key risks include government approval of acquisition and volatile shipping rates.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →ZIM is a global container liner shipping company that employs a 'global-niche' strategy, focusing on specific trade lanes where it holds a competitive advantage. Unlike larger, asset-heavy competitors, ZIM operates an agile, charter-intensive fleet, allowing it to rapidly adjust capacity to market demand while prioritizing digitalization and specialized cargo like refrigerated (reefer) goods.
Read more on ZIM →